ArticlePharmaceutical medicine2025

The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022.

Yazeed Ghawaa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.